GLAXO.BO GlaxoSmithKline Pharmaceuticals Limited
Healthcare · Drug Manufacturers - General
2649.00
-0.77%
Informazioni sull'azienda
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is based in Mumbai, India.
Intervallo 52 settimane
Analisi approfondita del dividendo
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO), a Drug Manufacturers - General company in the Healthcare sector, currently offers a dividend yield of 2.15%. Its dividend safety status is rated as "watch." The company has a momentum score of 6.7 on a 0-10 scale, indicating a positive recent price trend. However, specific value metrics to assess whether the stock is cheap or rich, and its current yield compared to its historical 5-year range, are not provided in the data.
Storico dei dividendi
Specific historical data regarding GlaxoSmithKline Pharmaceuticals Limited's dividend growth and consistency is not provided. The dividend history object is empty, and there is no information available on a dividend streak in years. Likewise, the 3-year and 5-year compound annual growth rates (CAGRs) for the dividend are not available in the provided data. The company's current annual dividend payment is 57.0 INR. Without this historical context, assessing the long-term trend or consistency of its dividend payments is not possible from the given information.
Sicurezza del dividendo
GlaxoSmithKline Pharmaceuticals Limited's dividend safety is rated as "watch." The company's payout ratio stands at 84.22% of its earnings per share, indicating that a substantial portion of earnings is allocated to dividends.
Quantic · Gratis
Leggi il resto sulla sicurezza del dividendo
In più i rischi principali e che cosa tenere d'occhio. Gratis, senza carta.
Generato dall'IA dai dati sui dividendi di Quantic · Aggiornato il 16 Nov 2026 · Informazioni, non consulenza finanziaria.
Mostrato in inglese — una traduzione è in arrivo.
Storico prezzi
Profilo del dividendo
Debito e leva finanziaria
Ultimi dati di bilancio pubblicati.
Nuovo negli investimenti in dividendi?
Informazioni, non consulenza finanziaria.
Quantic · Gratis
Monitora GLAXO.BO e tutto il tuo portafoglio
Rendimento reale, sicurezza del dividendo, reddito netto d'imposta e il tuo percorso verso la libertà — gratis, senza connessione al broker.
Ti serve di più? Pro aggiunge portafogli, monitoraggio del reddito da opzioni e più AI. Scopri Pro →